Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) EBIT (2020 - 2025)

Candel Therapeutics' EBIT history spans 4 years, with the latest figure at -$10.3 million for Q4 2023.

  • On a quarterly basis, EBIT fell 27.37% to -$10.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$38.4 million, a 10.57% decrease, with the full-year FY2025 number at -$48.3 million, down 44.63% from a year prior.
  • EBIT hit -$10.3 million in Q4 2023 for Candel Therapeutics, down from -$8.9 million in the prior quarter.
  • Over the last five years, EBIT for CADL hit a ceiling of -$2.6 million in Q2 2020 and a floor of -$10.3 million in Q4 2023.
  • Historically, EBIT has averaged -$7.4 million across 4 years, with a median of -$8.1 million in 2022.
  • Biggest five-year swings in EBIT: crashed 192.07% in 2021 and later rose 0.23% in 2023.
  • Tracing CADL's EBIT over 4 years: stood at -$6.1 million in 2020, then dropped by 26.37% to -$7.7 million in 2021, then decreased by 4.66% to -$8.1 million in 2022, then decreased by 27.37% to -$10.3 million in 2023.
  • Business Quant data shows EBIT for CADL at -$10.3 million in Q4 2023, -$8.9 million in Q3 2023, and -$9.6 million in Q2 2023.